DK1114062T3 - Modificeret E. coli-enterotoksin II-signalpeptid og en mikroorganisme, som eksprimerer et fusionsprotein af peptidet og et heterologt protein - Google Patents

Modificeret E. coli-enterotoksin II-signalpeptid og en mikroorganisme, som eksprimerer et fusionsprotein af peptidet og et heterologt protein

Info

Publication number
DK1114062T3
DK1114062T3 DK99944889T DK99944889T DK1114062T3 DK 1114062 T3 DK1114062 T3 DK 1114062T3 DK 99944889 T DK99944889 T DK 99944889T DK 99944889 T DK99944889 T DK 99944889T DK 1114062 T3 DK1114062 T3 DK 1114062T3
Authority
DK
Denmark
Prior art keywords
modified
peptide
heterologous protein
signal peptide
coli enterotoxin
Prior art date
Application number
DK99944889T
Other languages
English (en)
Inventor
Se Chang Kwon
Sung Youb Jung
Hoon Shin
Ki Doo Choi
Gwan Sun Lee
Jay Do Choi
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Application granted granted Critical
Publication of DK1114062T3 publication Critical patent/DK1114062T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/034—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the periplasmic space of Gram negative bacteria as a soluble protein, i.e. signal sequence should be cleaved
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
DK99944889T 1998-09-15 1999-09-15 Modificeret E. coli-enterotoksin II-signalpeptid og en mikroorganisme, som eksprimerer et fusionsprotein af peptidet og et heterologt protein DK1114062T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1019980038061A KR100316347B1 (ko) 1998-09-15 1998-09-15 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
PCT/KR1999/000547 WO2000015661A1 (en) 1998-09-15 1999-09-15 Modified e. coli enterotoxin ii signal peptide and a microorganism expressing a fusion protein of said peptide and a heterologous protein

Publications (1)

Publication Number Publication Date
DK1114062T3 true DK1114062T3 (da) 2006-06-06

Family

ID=36120918

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99944889T DK1114062T3 (da) 1998-09-15 1999-09-15 Modificeret E. coli-enterotoksin II-signalpeptid og en mikroorganisme, som eksprimerer et fusionsprotein af peptidet og et heterologt protein

Country Status (14)

Country Link
US (1) US6605697B1 (da)
EP (1) EP1114062B1 (da)
JP (1) JP3701201B2 (da)
KR (1) KR100316347B1 (da)
CN (1) CN1144815C (da)
AT (1) ATE317398T1 (da)
AU (1) AU754435B2 (da)
BR (1) BRPI9913698B1 (da)
CA (1) CA2342537C (da)
DE (1) DE69929805T2 (da)
DK (1) DK1114062T3 (da)
NZ (1) NZ510385A (da)
RU (1) RU2198179C2 (da)
WO (1) WO2000015661A1 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6242177B1 (en) * 1995-03-01 2001-06-05 Genentech, Inc. Methods and compositions for secretion of heterologous polypeptides
KR100356140B1 (ko) * 1999-07-08 2002-10-19 한미약품공업 주식회사 인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
KR100360594B1 (ko) * 2000-01-19 2002-11-13 한미약품공업 주식회사 인간 인터페론 알파의 발현 분비벡터 및 이를 이용한인터페론 알파의 생산 방법
KR100570422B1 (ko) * 2003-10-16 2006-04-11 한미약품 주식회사 대장균 분비서열을 이용하여 항체 단편을 분비·생산하는 발현벡터 및 이를 이용하여 항체 단편을 대량 생산하는 방법
BRPI0406605B8 (pt) 2003-11-13 2021-05-25 Hanmi Holdings Co Ltd conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
US8110665B2 (en) 2003-11-13 2012-02-07 Hanmi Holdings Co., Ltd. Pharmaceutical composition comprising an immunoglobulin FC region as a carrier
LT2049148T (lt) 2006-07-06 2016-11-25 Daewoong Co., Ltd. Žmogaus augimo hormono skysta stabili kompozicija
US20080124355A1 (en) 2006-09-22 2008-05-29 David Gordon Bermudes Live bacterial vaccines for viral infection prophylaxis or treatment
US8241623B1 (en) 2009-02-09 2012-08-14 David Bermudes Protease sensitivity expression system
US8524220B1 (en) 2010-02-09 2013-09-03 David Gordon Bermudes Protease inhibitor: protease sensitivity expression system composition and methods improving the therapeutic activity and specificity of proteins delivered by bacteria
US9597379B1 (en) 2010-02-09 2017-03-21 David Gordon Bermudes Protease inhibitor combination with therapeutic proteins including antibodies
US8771669B1 (en) 2010-02-09 2014-07-08 David Gordon Bermudes Immunization and/or treatment of parasites and infectious agents by live bacteria
KR101831300B1 (ko) 2010-10-29 2018-02-23 한미사이언스 주식회사 재조합 대장균으로부터 인간 과립구 콜로니 자극인자를 정제하는 방법
US9593339B1 (en) 2013-02-14 2017-03-14 David Gordon Bermudes Bacteria carrying bacteriophage and protease inhibitors for the treatment of disorders and methods of treatment
US9737592B1 (en) 2014-02-14 2017-08-22 David Gordon Bermudes Topical and orally administered protease inhibitors and bacterial vectors for the treatment of disorders and methods of treatment
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
WO2017180587A2 (en) 2016-04-11 2017-10-19 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EA037848B1 (ru) 2016-07-14 2021-05-27 Общество С Ограниченной Ответственностью "Биохимический Агент" Гибридный белок, полинуклеотид, генетическая конструкция, продуцент, препарат для регенерации хряща (варианты)
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
AU2018227583B2 (en) 2017-03-03 2023-06-01 Obsidian Therapeutics, Inc. CD19 compositions and methods for immunotherapy
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
BR112021017744A2 (pt) 2019-03-08 2021-11-16 Obsidian Therapeutics Inc Composições e métodos de cd40l para regulação ajustável
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2020252404A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CA3140668A1 (en) 2019-06-12 2020-12-17 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US12285437B2 (en) 2019-10-30 2025-04-29 The Research Foundation For The State University Of New York Reversing the undesirable pH-profile of doxorubicin via activation of a disubstituted maleamic acid prodrug at tumor acidity
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CA3202364A1 (en) 2020-12-15 2022-06-23 Arvada Therapeutics, Inc. Dsg2 compositions and methods for the treatment of covid-19
MX2024005327A (es) 2021-11-02 2024-05-21 Arvada Therapeutics Inc Composiciones y metodos de dsg2.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308835A (en) * 1984-07-09 1994-05-03 Praxis Biologics, Inc. Production of the E. coli LT-B enterotoxin subunit
EP0177343B1 (en) * 1984-10-05 1992-07-22 Genentech, Inc. Dna, cell cultures and methods for the secretion of heterologous proteins and periplasmic protein recovery
JPS63230089A (ja) * 1987-03-18 1988-09-26 Takeda Chem Ind Ltd 分泌発現による蛋白質の製造法
JPH0479898A (ja) * 1990-07-23 1992-03-13 Kitasato Inst:The コレラ菌及び毒素原性大腸菌を同時検出するためのdna及びrnaプローブとそれらを用いたコレラ菌及び毒素原性大腸菌の検出方法
EP0626448A3 (de) * 1993-05-26 1998-01-14 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung und Reinigung von alpha-Interferon

Also Published As

Publication number Publication date
EP1114062A1 (en) 2001-07-11
KR100316347B1 (ko) 2002-08-27
AU754435B2 (en) 2002-11-14
US6605697B1 (en) 2003-08-12
JP3701201B2 (ja) 2005-09-28
CA2342537C (en) 2008-07-08
BR9913698A (pt) 2002-01-29
CN1318070A (zh) 2001-10-17
ATE317398T1 (de) 2006-02-15
DE69929805T2 (de) 2006-10-26
EP1114062B1 (en) 2006-02-08
RU2198179C2 (ru) 2003-02-10
BRPI9913698B1 (pt) 2016-06-21
CA2342537A1 (en) 2000-03-23
JP2002538765A (ja) 2002-11-19
KR20000019788A (ko) 2000-04-15
AU5761899A (en) 2000-04-03
WO2000015661A1 (en) 2000-03-23
NZ510385A (en) 2002-12-20
CN1144815C (zh) 2004-04-07
DE69929805D1 (de) 2006-04-20

Similar Documents

Publication Publication Date Title
ATE317398T1 (de) Modifiziertes e.coli enterotoxin ii signalpeptid sowie ein mikroorganismus der ein fusionsprotein sowie ein heterologes protein exprimiert
CN100500853C (zh) 用于向细菌培养物上清液中分泌目的蛋白质的融合蛋白质
EP0722461A4 (en) EXPRESSION OF FUSION POLYPEPTIDES TRANSPORTED OUT OF CYTOPLASM WITHOUT HEAD SEQUENCE
AU7550098A (en) System for expressing hyperthermostable protein
PT1124941E (pt) Processo para recuperar polipeptidos heterologos a partir de celulas bacterianas
DE60142971D1 (de) Expression biologisch aktiver polypeptide in wasserlinse
EP0824148A3 (en) Polyester synthase gene and process for producing polyester
DK0786009T3 (da) Fremgangsmåde til bakteriel fremstilling af heterologe polypeptider med disulphidbindinger
NO963225L (no) Multivariant IL-3 hematopoiese-fusjonsprotein
RU2001110120A (ru) Модифицированный сигнальный пептид энтеротоксина-ii e. coli и микроорганизм, экспрессирующий белок слияния упомянутого пептида с гетерологичным белком
AU1003888A (en) Pancreatic secretory trypsin inhibitor and variants thereof produced by a recombinant host, process, expression vector and recombinant host therefore and pharmaceutical use thereof
RU2144957C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК pPINS07, КОДИРУЮЩАЯ ГИБРИДНЫЙ ПОЛИПЕПТИД, СОДЕРЖАЩИЙ ПРОИНСУЛИН ЧЕЛОВЕКА, И ШТАММ БАКТЕРИЙ Escherichia coli - ПРОДУЦЕНТ ГИБРИДНОГО ПОЛИПЕПТИДА, СОДЕРЖАЩЕГО ПРОИНСУЛИН ЧЕЛОВЕКА
IL141869A0 (en) Mammalian transforming growth factor beta-9 (ztgfss9)
IL99079A0 (en) Protein structure of the plant toxin gelonin
BG101226A (bg) Метод за производство на модифициран инхибитор палидипин на колагениндуцирано тромбоцитно натрупване
ITMI930456A1 (it) Vettore ricombinante e suo impiego per la preparazione esocellulare di anticorpi in forma di singola molecola da bacillus subtilis
CA2327524A1 (en) Method of controlling cleavage by ompt protease
DK0828004T3 (da) Proteindisulfidisomerase-gen afledt af stamme af methylotrof gær
WO2002101058A1 (fr) Nouveau promoteur
AU639969B2 (en) A novel vector to produce biologically important peptides
RU93032287A (ru) Способ получения окситоцина и рекомбинантные плазмидные днк ptoteilox и штаммы escherichia coli tg1/ptoteilox для его осуществления
SHULTZ THE AMINO ACID SEQUENCE OF THE TYROSINE-SENSITIVE 3-DEOXY-D-ARABINO-HEPTULOSONATE 7-PHOSPHATE SYNTHASE FROM ESCHERICHIA COLI K12
WO2002026978A1 (en) Novel proteins, genes encoding them and method of using the same
KR960034215A (ko) 헬리코박터 필로리의 항원결정부위 융합단백질인 Ub-A545의 유전공학적 제조방법
CA2034385A1 (en) Vector to produce biologically important peptides